Clincosm LogoSign in Get a demo

Molecular Mechanisms Underpinning Sarcopenic Obesity

Sponsor
The Swedish School of Sport and Health Sciences (Other)
Overall Status
Recruiting
CT.gov ID
NCT06120647
Collaborator
(none)
60
Enrollment
1
Location
71.1
Anticipated Duration (Months)
0.8
Patients Per Site Per Month

Study Details

Study Description

Brief Summary

The coexistence of obesity and sarcopenia results in sarcopenic obesity, a high-risk geriatric condition associated with metabolic perturbations and several co-morbidities. Despite the rising numbers of older adults diagnosed with sarcopenic obesity, few studies have characterized this condition on the muscle cell and systemic level. This study sought to comprehensively assess the influence of sarcopenic obesity on muscle and blood-related parameters and compare it to non-sarocopenic obese and non-sarcopenic lean older adults.

Condition or Disease Intervention/Treatment Phase
  • Dietary Supplement: Essential amino acids (EAA)

Study Design

Study Type:
Observational
Anticipated Enrollment :
60 participants
Observational Model:
Case-Control
Time Perspective:
Cross-Sectional
Official Title:
Molecular Mechanisms Underpinning Sarcopenic Obesity
Actual Study Start Date :
Jan 28, 2020
Anticipated Primary Completion Date :
Dec 15, 2025
Anticipated Study Completion Date :
Dec 30, 2025

Arms and Interventions

Arm Intervention/Treatment
Sarcopenic obesity

Age: 70-80 years Men, ALM/W < 25.7 %, body fat % > 35 Women, ALM/W < 19.7 %, body fat % > 40

Dietary Supplement: Essential amino acids (EAA)
intake of 240 mg EAA per kg lean body mass after a resistance exercise session
Non-sarcopenic obese

Age: 70-80 years Men, ALM/W > 25.7 %, body fat % > 35 Women, ALM/W > 19.7 %, body fat % > 40

Dietary Supplement: Essential amino acids (EAA)
intake of 240 mg EAA per kg lean body mass after a resistance exercise session
Non-sarcopenic lean

Age: 70-80 years Men, ALM > 7.0 kg/m2, body fat % < 25 Women, ALM > 5.5 kg/m2, body fat % < 32

Dietary Supplement: Essential amino acids (EAA)
intake of 240 mg EAA per kg lean body mass after a resistance exercise session
Young lean

Age: 18-40 years Men, ALM > 7.0 kg/m2, body fat % < 25 Women, ALM > 5.5 kg/m2, body fat % < 32

Dietary Supplement: Essential amino acids (EAA)
intake of 240 mg EAA per kg lean body mass after a resistance exercise session

Outcome Measures

Primary Outcome Measures

  1. Fiber type-specific cell signalling [3 hour]

    This measure will be investigated during an experimental trial in which the participants are subjected to an acute bout of resistance exercise followed by the ingestion of essential amino acids (240 mg/kg lean mass). During this 3 hour time period, the participants will donate two muscle biopsies, one before exercise and the second one 1 hour after exercise. Cell signalling networks related to muscle mass regulation will be examined in these biopsy samples. The signal will be measured using Western blotting and the signal obtained is expressed in relation to baseline (adjusted volume intensity).

Secondary Outcome Measures

  1. Skeletal muscle fiber characteristics [3 hour]

    Fiber type-specific area measured using immunofluorescence microscope. Unit of measurement is square micrometers (µm2).

  2. Whole body muscle volume [1 hour]

    Indices of muscle volume and fat infiltration obtained with magnetic resonance imaging (MRI). Unit of measurement is cubic centrimeters (Cm3).

  3. Whole body glucose tolerance [2 hours]

    Oral glucose tolerance test in which the participants will ingest a standardized glucose drink and blood glucose levels will be monitored throughout a period of 2 hours. Unit of measurement is mmol/L glucose.

  4. Accelerometer-assessed physical activity levels [1 week]

    Hip-worn accelerometer data (Actigraph GT3X) collected over 7 consecutive days. Unit of measurement is steps per day.

  5. Isometric and isokinetic leg muscle strength [1 hour]

    Muscle performance will be evaluated at a single timepoint during the study using IsoMed2000 dynamometer. Participants will perform a maximal isometric contraction at 60 degrees of knee flexion. Unit of measurement is Newton meter (N-m).

Eligibility Criteria

Criteria

Ages Eligible for Study:
18 Years to 80 Years
Sexes Eligible for Study:
All
Inclusion Criteria:

  • Body fat % in accordance with previously defined criteria

  • Free of smoking (since 10 years)

  • Able to walk without assistance

  • Able to perform bilateral leg extension exercise

Exclusion Criteria:

  • History of or present disease of myocardial, vascular, endocrine, hepatic, renal, pulmonary or neuromuscular origin

  • Uncontrolled hypo/hypertension

  • Use of anticoagulants (Warfarin, Trombyl)

  • Use of metformin or other anti-diabetic medications

  • Poor appetite and unexplained weight loss (4,5 kg) over the past 6 months

  • Active malignancy

  • Present infection

  • Dementia or delirium

  • Other conditions that may interfere with the study protocol in the opinion of the PI

Contacts and Locations

Locations

Site City State Country Postal Code
1 The Swedish School of Sport and Health Sciences Stockholm Sweden 11433

Sponsors and Collaborators

  • The Swedish School of Sport and Health Sciences

Investigators

  • Principal Investigator: William Apró, PhD, The Swedish School of Sport and Health Sciences and Karolinska Institute, Stockholm Sweden

Study Documents (Full-Text)

More Information

Publications

None provided.
Responsible Party:
William Apro, Associate Professor, The Swedish School of Sport and Health Sciences
ClinicalTrials.gov Identifier:
NCT06120647
Other Study ID Numbers:
  • 2019-04016
First Posted:
Nov 7, 2023
Last Update Posted:
Nov 7, 2023
Last Verified:
Nov 1, 2023
Studies a U.S. FDA-regulated Drug Product:
No
Studies a U.S. FDA-regulated Device Product:
No
Additional relevant MeSH terms:
Sarcopenia
Obesity

Study Results

No Results Posted as of Nov 7, 2023